Sonja Wind

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial setbacks and trimmed the top end of guidance for its life sciences unit.

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

A pilot project of the four-day work week in Germany found that almost three quarters of participants aren’t returning to a five-day standard.

A six-month trial in Germany showed many promising signs. But there were disappointments, too.

The German economy ministry aims to bolster domestic investment by providing 10% of the funds directly to companies, in the latest plan to revive economic growth.

Adidas AG reported strong third-quarter growth across most regions in a sign a revival plan led by Chief Executive Officer Bjorn Gulden is starting to work.

BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.

Bayer AG cut its profit outlook for the year on stubbornly low prices for agriculture products, including the controversial weedkiller Roundup.

Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside positive growth trends in its other two businesses.

Eisai Co. and its partners won the European Union regulator’s backing for use of its Alzheimer’s drug Leqembi in a surprising reversal of a previously negative opinion.